Literature DB >> 3520318

The effects of antihypertensive therapy on the quality of life.

S H Croog, S Levine, M A Testa, B Brown, C J Bulpitt, C D Jenkins, G L Klerman, G H Williams.   

Abstract

We conducted a multicenter randomized double-blind clinical trial among 626 men with mild to moderate hypertension to determine the effects of captopril, methyldopa, and propranolol on their quality of life. Hydrochlorothiazide was added if needed to control blood pressure. After a 24-week treatment period, all three groups had similar blood-pressure control, although fewer patients taking propranolol required hydrochlorothiazide. Patients taking captopril alone or in combination with a diuretic were least likely to withdraw from treatment because of adverse effects (8 percent vs. 20 percent for methyldopa and 13 percent for propranolol). The treatment groups were similar in scores for sleep dysfunction, visual memory, and social participation. However, patients taking captopril, as compared with patients taking methyldopa, scored significantly higher (P less than 0.05 to less than 0.01) on measures of general well-being, had fewer side effects, and had better scores for work performance, visual-motor functioning, and measures of life satisfaction. Patients taking propranolol also reported better work performance than patients taking methyldopa. Patients taking captopril reported fewer side effects and less sexual dysfunction than those taking propranolol and had greater improvement (P less than 0.05 to less than 0.01) on measures of general well-being. Our findings show that antihypertensive agents have different effects on the quality of life and that these can be meaningfully assessed with available psychosocial measures.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3520318     DOI: 10.1056/NEJM198606263142602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  249 in total

1.  Quality of life assessment in adults with type 1 Gaucher disease.

Authors:  B J Masek; K B Sims; C M Bove; M S Korson; P Short; D K Norman
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 2.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 3.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  What are the elements of good treatment for hypertension?

Authors:  C D Mulrow; M Pignone
Journal:  BMJ       Date:  2001-05-05

Review 5.  Measuring handicap: motives, methods, and a model.

Authors:  R H Harwood; S Jitapunkul; E Dickinson; S Ebrahim
Journal:  Qual Health Care       Date:  1994-03

6.  Self-report assessment of female sexual function: psychometric evaluation of the Brief Index of Sexual Functioning for Women.

Authors:  J F Taylor; R C Rosen; S R Leiblum
Journal:  Arch Sex Behav       Date:  1994-12

Review 7.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

8.  Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians.

Authors:  Peter A Ubel; Christopher Jepson; David A Asch
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

9.  Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension.

Authors:  E J Pérez-Stable; T J Coates; R B Baron; B S Biró; W W Hauck; K S McHenry; P S Gardiner; D Feigal
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

10.  Transcriptional activation of low density lipoprotein receptor gene by angiotensin-converting enzyme inhibitors and Ca(2+)-channel blockers involves protein kinase C isoforms.

Authors:  L H Block; R Keul; M Crabos; R Ziesche; M Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.